Seeking Alpha

Xuhua Zhou

 
View as an RSS Feed
View Xuhua Zhou's Comments BY TICKER:
Latest  |  Highest rated
  • Illegal Products Could Spell Big Trouble At Lumber Liquidators [View article]
    Also why is this coming from an equity analyst instead of a formal press release from the Company. Btw, I have not been contacted by the company....I may ask for refund on the box I spent 120 dollar buying from them...
    Jun 21 12:24 PM | 1 Like Like |Link to Comment
  • Illegal Products Could Spell Big Trouble At Lumber Liquidators [View article]
    http://bit.ly/12fNNVc

    Piper Jaffary analyst responded to the note and I think the argument merits investors attention. Piper analyst notes three things.
    1. quality control taken seriously at LL. I find this to be hilarious given all consumers hate their products and the sheer number of the complaints that are readily available for everybody to read. EVERYBODY IS COMPLAINING ABOUT PRODUCT QUALITY. Also the analyst notes CARB phase 2 is a higher standard than CARB phase 1. CARB phase 2 is required to sell products in the state of california. LL may have been able to get rubber stamped for compliance but as a consumer walks into the store of LL, I'm sure he or she cares more about whether the product he purchases is actually compliant.
    2. Extensive testing is completed. To respond to this, I have no knowledge on LL's internal quality control. Don't think doing enough testing is a good argument against toxic products.
    3. Testing suffers from sampling error. The response, of course the testing suffers from sampling error as are the case with all testings. It costs a significant amount of money to test a single product and buying and moving around 70 pound boxes isn't exactly an easy task either. Again, it's not my job to be the company's quality controller. Finally I just want to note the absurdity of the analyst's argument that it's ok to have some noncompliant products. I'm curious whether Mr. Keith would want to take the chance with changing his flooring into LL's flooring if there's let's say a 10% probability those floors will emit carcinogenic chemical to him, his family and kids for the next 10 years. Bottom line is this, you cannot have a single product that's noncompliant.
    Jun 21 12:19 PM | 2 Likes Like |Link to Comment
  • Illegal Products Could Spell Big Trouble At Lumber Liquidators [View article]
    Not to mention how expensive it is....
    Jun 21 10:29 AM | Likes Like |Link to Comment
  • Illegal Products Could Spell Big Trouble At Lumber Liquidators [View article]
    Additional Letters addressed to congressional members:

    http://bit.ly/13XybKv
    http://bit.ly/13XyeFT
    http://bit.ly/13Xyd50
    Jun 21 07:58 AM | Likes Like |Link to Comment
  • Illegal Products Could Spell Big Trouble At Lumber Liquidators [View article]
    John,

    Thanks for the comment. I would agree with you if the lab test was merely an isolated incident and LL is widely praised by consumers in general. The situation, however, is the complete opposite. As I noted in the article, the formaldehyde issue should not be new for LL's management. There has been extensive amount of document complaints online with regards to formaldehyde complaints related specifically to Lumber Liquidators. You could not find the similar complaints if you search for Lowes and Home Depot products. They are extremely telling and would make mockery of the response you suspected the management may post. Frankly, the lab test is merely a way to certify LL as major violator of the relevant laws and regulations. It can now be presented to the regulators to show, in addition to consumer complaints, the products sold at LL are factually noncompliant. That is important. Also, you may have underestimated the ease at which 210 million dollar worth of inventory could be tested...
    Jun 21 01:23 AM | 1 Like Like |Link to Comment
  • Illegal Products Could Spell Big Trouble At Lumber Liquidators [View article]
    Thanks for the comments. We will see if the Company comes out and address the issues raised here. It's my view the Company's expansion plans should be put on hold immediately pending further audit of its quality assurance procedures. It is not OK to sell toxic flooring products to consumers. I have copied contents to relevant regulatory agencies and members of congress. Would be interesting to see how they respond.
    Jun 21 01:01 AM | Likes Like |Link to Comment
  • Ampio Pharmaceuticals: 50 Shades Of Grey - Secondary On The Way [View article]
    Do you have any literature that you can reference to show that fact? I paper I referenced used clinical data to support the lack of correlation..
    Jun 12 03:37 PM | Likes Like |Link to Comment
  • Ampio Pharmaceuticals: 50 Shades Of Grey - Secondary On The Way [View article]
    What is your point here. I read your comment and you said nothing..Which specific data point in those papers i referenced is unfounded? Those are clearly contradicting to the Company's trial programs and I would love for you to explain why those are not issues??
    Jun 10 12:01 AM | Likes Like |Link to Comment
  • Ampio Pharmaceuticals: 50 Shades Of Grey - Secondary On The Way [View article]
    I think your comment's the exact type of comment that's not worthy of anybody's time to read. If you have any insights, make your case. Otherwise, your talk is cheap..
    Jun 9 09:09 PM | 1 Like Like |Link to Comment
  • Ampio Pharmaceuticals: 50 Shades Of Grey - Secondary On The Way [View article]
    This has nothing to do with who knows more who knows less. The paper referenced above are written by experts in the field and they are backed up by data. I've got no beef about the fact Optina was somewhat effective in reducing the retina thickness, but the paper I referenced clearly shows the weak to no correlation between retina thickness and visual acuity, which is the primary end point in the 3rd trial. I'm sure the CTO at the Company knows that as well but obviously his incentives are skewed in taking the drug into phase 3. Again I did not say Zertane is ineffectively, I'm again quoting papers that show much greater efficacy of a generic drug...What's the point of developing a drug when there's a much better and cheaper alternative in the market already..It would be the equivalent of selling a computer that's a third of the performance but three times the price..who's gonna buy it??
    Jun 9 04:07 PM | Likes Like |Link to Comment
  • Ampio Pharmaceuticals: 50 Shades Of Grey - Secondary On The Way [View article]
    How is the "facts" and "data" confusing to people? Those are published papers that show tramadol HCI gets much more superior results and the fact retina thickness has very weak to none correlation with vision acuity...People who are betting on AMPE's success in developing those drugs should understand the implication of the papers i referenced above.
    Jun 7 03:32 PM | Likes Like |Link to Comment
  • Ampio Pharmaceuticals: 50 Shades Of Grey - Secondary On The Way [View article]
    I don't get the response of the management. It did not address many issues raised in the article and instead went straight for the author of an article written two years ago. Among the issues with their drug pipeline. Zertane is show to be inferior to Tramadol HCI and Optina's phase II has zero bearing on the primary end point in phase III...The Company appears to be a house of cards that is waiting to collapse...

    Zertane appears to be a joke. If you read the paper published by Bar-Or in 2011 and compared the results to a paper published in 2007.

    Bar-Or's study of tramadol ODT end results :

    Results and limitations: Tramadol ODT resulted in significant increases in median IELT
    compared with placebo; increases were 0.6 min (1.6 fold), 1.2 min (2.4 fold), and 1.5 min
    (2.5 fold) for placebo, 62 mg tramadol ODT, and 89 mg tramadol ODT, respectively
    (p < 0.001 for all comparisons). Men saw significantly greater improvement in all four
    measures of the PEP in both doses compared with placebo (p < 0.05 for all comparisons).
    Tramadol ODT was well tolerated; study discontinuation occurred in 0%, 1.0%, and 1.6%
    of subjects in placebo, 62 mg, and 89 mg tramadol ODT groups, respectively. Limitations
    include study inclusion for men with IELT up to 120 s.

    07 study use tramadol HCI:

    Results. The baseline (mean ± SD) IELT for patients before treatment was 1.17 ± 0.39 minutes. At the end of the
    treatment period utilizing the active drug, the mean IELT was increased significantly in patients on Tramadol
    treatment to 7.37 ± 2.53 minutes. The same patients on placebo medication had mean IELT of only
    2.01 ± 0.71 minutes. Patients uniformly reported satisfaction with their resulting control over ejaculation.

    So let me get this straight, the generic tramadol provide results 3x better than the ODT and they are trying to get that drug approved??

    A specific discussion section on Bar-Or's paper:

    Salem et al. previously examined the safety and efficacy
    of the same active ingredient present in tramadol ODT
    (tramadol HCl) for the treatment of PE [7]. Their AE rate in
    patients taking the study drug (13%) was similar to our
    study (12–16%). The authors examined the efficacy of the
    study drug by comparing mean changes in mean IELT by
    treatment group. It is well known that IELT is highly
    positively skewed and the mean IELT is an inappropriate
    estimator of effect size; we repeated their analyses for
    comparison purposes only. Salem and colleagues reported a
    mean end point IELT of 7.4 min with 25 mg tramadol HCl;
    these findings are disparate from ours (3.8 min for 62 mg
    tramadol ODT and 3.9 min for 89 mg tramadol ODT).

    http://bit.ly/114pcUd

    Abstract
    AIMS:
    To investigate the correlation between increased retinal thickness (RT) measured with spectral domain high-definition optical coherence tomography (OCT) (Cirrus HD-OCT (Carl Zeiss Meditec, Dublin, California, USA)) and best-corrected visual acuity (BCVA) in eyes with clinically significant macular oedema (CSME) and type 2 diabetes.
    METHODS:
    Seventy eyes with CSME were included in this observational study. Sixty-two eyes were considered for analysis and were classified as having/not having retinal thickening in the central fovea (central 500-microm-diameter circle) by Cirrus HD-OCT. RT measurements were computed and correlated with BCVA. For comparison purposes, the Stratus OCT (Carl Zeiss Meditec, Dublin, California, USA) central point thickness was also obtained in these eyes.
    RESULTS:
    In the 19 eyes with CMSE identified by Cirrus HD-OCT without increased RT in the central fovea (500-microm-diameter circle), no correlation was found between RT and BCVA (R=0.062; 95% CI -0.404 to 0.502). In the 43 eyes where the Cirrus HD-OCT identified an increased RT in the central fovea (central 500-microm-diameter circle), only a moderate correlation between RT and BCVA was found (R=-0.459; 95% CI -0.667 to -0.184).
    CONCLUSION:
    Correlations between RT and BCVA in CSME are only present when the central 500-microm-diameter circle is involved. However, even in this circumstance, a correlation was found in only 48.8% of the cases. RT cannot, therefore, be used as a surrogate outcome for visual acuity changes.
    Jun 7 01:05 PM | 3 Likes Like |Link to Comment
  • HCI Group: Inadequate Reinsurance Coverage Poses Potentially Catastrophic Risks To Shareholders, Policyholders And Taxpayers [View article]
    http://bit.ly/1135Uid
    http://bit.ly/19O8u21

    The stories read like dejavu for HCI...When Poe went under, 20 thousand policies went unpaid..
    Jun 7 03:20 AM | 1 Like Like |Link to Comment
  • Uni-Pixel: A Picture Is Worth A Thousand Words [View article]
    I think this article clearly shows the validity of my point 2. It will be further proven in the next few months when Unipixel fails to produce anything.
    On point three, it is factually true they only have one approved patent relevant to UniBoss. The rest of the patents are all pending. Carlco lawsuit has not gone away. It has been moved to a state court but no judgement's been rendered on the validity of the infringement claims.
    Point 1 is subject to debates. I cited data from other parties as well as prior projection by Unipixel's own management. The market is changing and evolving.

    The second article bears significance beyond the lawsuit itself. It shows the lack of reliability of the management team. The complaint itself was very telling. Either way, I think the scam probably got a few weeks, maybe months to go. You bet there will be an ensuing SEC investigation on the management after this thing unravels and it will be clear by then who's the one that's been telling the truth.
    Jun 2 02:32 AM | Likes Like |Link to Comment
  • Uni-Pixel: A Picture Is Worth A Thousand Words [View article]
    You keep on saying my article has been proven false. How so? If anything, the Company's announcement in delaying products on shelf proves my point that they do not, have never had, a viable technology. The Company is a serial partnership signer..unfortunately signing partnership is not a business.
    Jun 2 12:44 AM | 3 Likes Like |Link to Comment
COMMENTS STATS
148 Comments
141 Likes